Pushpa Itagi

Pushpa Itagi

Auto-generated profile, based on publicly available information

Pushpa Itagi

Division of Public Health Sciences, Fred Hutchinson Cancer Center, 1100 Fairview Ave. N, Seattle, WA 98109

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
HLHyun Jung Lee
Hyun Jung Lee
RGRoman Gulati
Roman Gulati
ESErolcan Sayar
Erolcan Sayar
RPRadhika A. Patel
Radhika A. Patel
PIPushpa Itagi
Pushpa Itagi
RRRuben Raychaudhuri
Ruben Raychaudhuri
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort (n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression (P = 0.2). In urothelial carcinoma (n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.

12 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RPRobert D. Patton
Robert D. Patton
ANAlexander Netzley
Alexander Netzley
TPThomas W. Persse
Thomas W. Persse
ANAkira Nair
Akira Nair
PGPatricia C. Galipeau
Patricia C. Galipeau
GHGavin Ha
Gavin Ha
Circulating tumor DNA (ctDNA) profiling from liquid biopsies is increasingly adopted as a minimally invasive solution for clinical cancer diagnostic applications. Current methods for inferring gene expression from ctDNA require specialized assays or ultra-deep, targeted sequencing, which preclude transcriptome-wide profiling at single-gene resolution. Herein we jointly introduce Triton, a tool for comprehensive fragmentomic and nucleosome profiling of cell-free DNA (cfDNA), and Proteus, a multi-modal deep learning framework for predicting single gene expression, using standard depth (∼30-120x) whole genome sequencing of cfDNA. By synthesizing fragmentation and inferred nucleosome positioning patterns in the promoter and gene body from Triton, Proteus reproduced expression profiles using pure ctDNA from patient-derived xenografts (PDX) with an accuracy similar to RNA-Seq technical replicates. Applying Proteus to cfDNA from four patient cohorts with matched tumor RNA-Seq, we show that the model accurately predicted the expression of specific prognostic and phenotype markers and therapeutic targets. As an analog to RNA-Seq, we further confirmed the immediate applicability of Proteus to existing tools through accurate prediction of gene pathway enrichment scores. Our results demonstrate the potential clinical utility of Triton and Proteus as non-invasive tools for precision oncology applications such as cancer monitoring and therapeutic guidance. Subjects: Circulating tumor DNA, liquid biopsies, patient-derived xenografts, whole genome sequencing, deep learning, convolutional neural network, gene expression

25 August 2025
Verified
Other
Open access
HLHyun Jung Lee
Hyun Jung Lee
RGRoman Gulati
Roman Gulati
ESErolcan Sayar
Erolcan Sayar
RPRadhika A. Patel
Radhika A. Patel
PIPushpa Itagi
Pushpa Itagi
RRRuben Raychaudhuri
Ruben Raychaudhuri
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

25 August 2025
Verified
Other
Open access
HLHyun Jung Lee
Hyun Jung Lee
RGRoman Gulati
Roman Gulati
ESErolcan Sayar
Erolcan Sayar
RPRadhika A. Patel
Radhika A. Patel
PIPushpa Itagi
Pushpa Itagi
RRRuben Raychaudhuri
Ruben Raychaudhuri
Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

25 August 2025
Verified
Other
Open access
HLHyun Jung Lee
Hyun Jung Lee
RGRoman Gulati
Roman Gulati
ESErolcan Sayar
Erolcan Sayar
RPRadhika A. Patel
Radhika A. Patel
PIPushpa Itagi
Pushpa Itagi
RRRuben Raychaudhuri
Ruben Raychaudhuri
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in (A) prostate cancer and (B) urothelial cancer.

25 August 2025
Verified
Other
Open access
HLHyun Jung Lee
Hyun Jung Lee
RGRoman Gulati
Roman Gulati
ESErolcan Sayar
Erolcan Sayar
RPRadhika A. Patel
Radhika A. Patel
PIPushpa Itagi
Pushpa Itagi
RRRuben Raychaudhuri
Ruben Raychaudhuri
A and B, Representative micrographs of HER2 IHC staining in prostate cancer (A) and urothelial cancer (B) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate (E) and urothelial (F) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.